[1] Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovarysyndrome: a position statement from the European Society of Endocrinology[J]. Eur J Endocrinol, 2014,171(4):1-29. [2] Hart R, Doherty D A, Mori T, et al. Extent of metabolic risk inadolescent girls with features of polycystic ovary syndrome[J].Fertil Steril,2011,95(7):2347-2353. [3] Li H W, Lee V C, Lau EY, et al. Role of baseline antral follicle countand anti-mullerian hormone in prediction of cumulative live birth inthe first in vitro fertilisation cycle: a retrospective cohort analysis[J]. PLoS One, 2013, 8(4): e61095. [4] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS) [J]. Hum Reprod, 2004, 19(1): 41-47. [5] 黄月勤. 临床流行病学[M]. 北京: 人民卫生出版社, 2014:157-160. [6] 余松林. 医学统计学[M]. 北京:人民卫生出版社,2002:164-178. [7] Dursun F, Güven A, Yildiz M. Assessment of anti-müllerianHormone level in management of Adolescents withPolycystic ovary syndrome[J]. J Clin Res Pediatr Endocrinol, 2016,8(1):55-60. [8] Pawelczak M, Kenigsberg L, Milla S, et al. Elevated serum anti-Müllerian hormone in adolescentswithpolycystic ovary syndrome: relationship toultrasoundfeatures[J].J Pediatr Endocrinol Metab, 2012,25(9-10):983-989. [9] Cassar S, Teede H J, Moran L J, et al. Polycystic ovary syndromeand anti-Müllerian hormone: role of insulin resistance,androgens, obesity and gonadotrophins[J]. ClinEndocrinol:Oxf, 2014, 81(6):899-906. [10] Roberts V J, Barth S, el-Roeiy A, et al. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle[J]. J Clin Endocrinol Metab, 1993, 77(5): 1402-1410. [11] Aylin Y, Çaðcil Y, Firdevs B, et al. Anti-müllerian hormone and lnhibin-A, but not inhibin-B or insulin like peptide-3, may be used as surrogates in the diagnosis of polycystic ovary syndrome in adolescents: preliminary results[J]. J Clin Res Pediatr Endocrinol 2016,8(3):288-297. [12] Magoffin D A, Jakimiuk A J. Inhibin A, inhibin B and activinA concentrations in follicular fluid from women withpolycystic ovary syndrome[J]. Hum Reprod,1998, 13(10):2693-2698. [13] Lockwood G M, Muttukrishna S, Groome N P, et al. Mid-follicular phase pulses of inhibin Bare absent in polycystic ovarian syndrome and are initiatedby successful laparoscopic ovarian diathermy: a possiblemechanism regulating emergence of the dominant follicle[J].J Clin Endocrinol Metab, 1998, 83(5):1730-1735. [14] Laven J S, Imani B, Eijkemans M J, et al.Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility[J]. Hum Reprod,2001, 16(7):1359-1364. [15] Welt C K, Taylor A E, Martin K A,et al. Serum inhibin Bin polycystic ovary syndrome: regulation by insulin andluteinizing hormone[J]. J Clin Endocrinol Metab, 2002, 87(12):5559-5565. [16] Hazout A, Bouchard P, Seifer D B, et al. Serumanti-mullerian hormone/mullerian-inhibiting substanceappears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulatinghormone, inhibin B, or estradiol[J]. Fertil Steril,2004,82(5):1323-1329. [17] Lambalk C B, Van Disseldorp J, de Koning C H, et al.Testing ovarian reserve to predict age at menopause[J]. Maturitas, 2009,63(4):280-291. [18] Pellatt L, Rice S, Mason H D. Anti-Müllerian hormone and polycystic ovary-syndrome: a mountain too high?[J]. Reproduction,2010,139(5):828-833. [19] 田玄玄,阮祥燕,王娟,等.437例多囊卵巢综合征相关因素调查分析[J].首都医科大学学报,2014,35(4):414-418. [20] 杨颖, 王金敏,彭书苹,等.肥胖型多囊卵巢综合征病人临床特征分析[J].中国煤炭工业医学杂志,2014,17(9):1453-1455. |